IRVINE, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Endologix, Inc. , developer of minimally invasive treatments for aortic disorders, announced today that it has conducted further evaluation of the patent infringement lawsuit filed against the company last week by Cook Medical, and of the patents asserted in the lawsuit. Based upon this evaluation, Endologix believes that the alleged infringement is without merit and the company intends to vigorously defend its position.
John McDermott, Endologix President and Chief Executive Officer, said, "We are pleased that our initial evaluation of these claims, which Cook Medical waited for years to assert, has already yielded support for numerous promising defenses."
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Additional information can be found on Endologix's Web site at www.endologix.com
Forward-Looking Statements
Except for historical information contained herein, this news release contains forward-looking statements, specifically related to the claims of alleged infringement. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.
SOURCE Endologix, Inc.
CONTACT: John McDermott, CEO, Endologix, Inc., +1-949-595-7200; or
Investors, Nick Laudico, +1-646-536-7030, or Zack Kubow, +1-646-536-7020,
both of The Ruth Group
Web site: http://www.endologix.com/
